Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-label, Single Dose, Parallel Group Study To Evaluate The Pharmacokinetics Of Glasdegib (Pf-04449913) In Subjects With Impaired Renal Function

Trial Profile

A Phase 1, Open-label, Single Dose, Parallel Group Study To Evaluate The Pharmacokinetics Of Glasdegib (Pf-04449913) In Subjects With Impaired Renal Function

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Oct 2018

At a glance

  • Drugs Glasdegib (Primary)
  • Indications Acute myeloid leukaemia; Cancer; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Colorectal cancer; Glioblastoma; Graft-versus-host disease; Haematological malignancies; Myelodysplastic syndromes; Myelofibrosis; Non-small cell lung cancer
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 26 Sep 2018 Status changed from recruiting to completed.
    • 30 Aug 2018 Planned End Date changed from 30 Sep 2018 to 19 Sep 2018.
    • 30 Aug 2018 Planned primary completion date changed from 30 Sep 2018 to 28 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top